Marksans Pharma on Tuesday said it has received an establishment inspection report (EIR) from the US health regulator for company's manufacturing facility in the US.
In a regulatory filing, the company announced "receipt of the EIR from US Food and Drug Administration (USFDA) in respect of inspection of company's manufacturing facility Time-Cap Laboratories Inc. located at Farmingdale, New York, USA carried out from December 5, 2019 to December 18, 2019".
The shares of the company were trading at Rs 23.20 apiece on BSE, up 4.98 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
